Retrospective analysis reveals delays in insurance approval impede access to intensive chemotherapy in AML patients, suggesting barriers to clinical trial enrollment.
Key Points
To analyze the effect of insurance authorization delays on treatment access for patients with newly diagnosed AML.
Retrospective chart review of insurance authorization requests for clinical trials in AML patients.
Evaluated claims for intensive chemotherapy treatment and recorded demographic features and insurance status.
Examined the time to insurance authorization by payor type and correlated socioeconomic status via Area Deprivation Index.
92% of insurance claims for clinical trial participation were authorized with a median authorization time of 1 calendar day.
75% of authorized patients received investigational therapy while 25% received standard of care.
Patients with Medicare had the shortest mean time to authorization compared to other payors.